Price (delayed)
$3.96
Market cap
$182.27M
P/E Ratio
0.05
Dividend/share
N/A
EPS
$78.85
Enterprise value
$139.11M
We are a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients. Our programs, platform technologies, and manufacturing strategy are designed to directly
There are no recent dividends present for CRGX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.